Wave Life Sciences (WVE) Expected to Announce Quarterly Earnings on Thursday

Wave Life Sciences (NASDAQ:WVE - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect Wave Life Sciences to post earnings of ($0.26) per share and revenue of $11.65 million for the quarter.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.34. The business had revenue of $83.75 million during the quarter, compared to the consensus estimate of $25.60 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. On average, analysts expect Wave Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Wave Life Sciences Trading Up 2.0 %

NASDAQ WVE traded up $0.16 during trading on Friday, hitting $8.10. 3,725,765 shares of the company's stock were exchanged, compared to its average volume of 1,241,252. The company has a market cap of $1.25 billion, a PE ratio of -7.30 and a beta of -0.91. Wave Life Sciences has a fifty-two week low of $4.25 and a fifty-two week high of $16.74. The stock's 50 day moving average price is $8.16 and its two-hundred day moving average price is $11.44.

Insiders Place Their Bets

In other news, Director Christian O. Henry sold 10,500 shares of Wave Life Sciences stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $9.77, for a total value of $102,585.00. Following the completion of the sale, the director now owns 16,115 shares in the company, valued at $157,443.55. The trade was a 39.45 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Paul Bolno sold 169,025 shares of the business's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the transaction, the chief executive officer now owns 338,351 shares in the company, valued at $3,238,019.07. The trade was a 33.31 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 29.10% of the company's stock.

Analyst Upgrades and Downgrades

WVE has been the topic of a number of research analyst reports. Wedbush began coverage on shares of Wave Life Sciences in a research report on Tuesday, April 8th. They issued an "outperform" rating and a $18.00 target price on the stock. Cantor Fitzgerald assumed coverage on Wave Life Sciences in a report on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 target price for the company. Jefferies Financial Group began coverage on Wave Life Sciences in a research report on Tuesday, February 25th. They issued a "buy" rating and a $26.00 target price for the company. StockNews.com upgraded Wave Life Sciences from a "sell" rating to a "hold" rating in a report on Saturday, March 8th. Finally, HC Wainwright reiterated a "buy" rating and issued a $22.00 price objective on shares of Wave Life Sciences in a report on Wednesday, March 26th. Two investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $21.17.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.